Oxford Medical Products Limited

Oxford Medical Products Limited develops advanced health solutions, focusing on innovative gastroretentive drug delivery technologies to combat obesity and enhance therapeutic outcomes. Founded in 2017 in the UK, Oxford Medical Products Limited specializes in gastroretentive drug delivery systems. The company has raised GBP 2. 5 million in Series A funding as the investment target, with investors including Ada Ventures and Selvedge Venture, valuing the firm at GBP 20 million.

The company has completed three deals, with its most recent funding round occurring on February 2, 2022. Nicholas Edwards is the founder, while Camilla Easter serves as CEO. Oxford Medical Products specializes in developing innovative health solutions utilizing their proprietary ‘Sirona’ gastroretentive hydrogel platform technology. This flagship product is currently undergoing human clinical trials as a weight-loss treatment aimed at addressing obesity and related health issues.

The Sirona technology also has potential applications in drug delivery systems for small molecules and biologics, as well as in the development of biosensors and nutraceutical delivery. The company primarily targets pharmaceutical developers and healthcare providers as its client base, focusing on markets in the United Kingdom with plans for future expansion. Oxford Medical Products generates revenue through partnerships with drug developers who utilize its hydrogel technology for gastroretentive drug delivery systems. The company operates on a business-to-business (B2B) model, collaborating directly with pharmaceutical firms to deliver active pharmaceutical ingredients (APIs) efficiently.

Transactions involve agreements where drug developers integrate the Sirona technology into their product offerings. Revenue generation is closely tied to the successful completion of clinical trials and subsequent commercialization of the technology, particularly as they relate to weight management and drug delivery applications. Oxford Medical Products Limited plans to leverage the GBP 2. 5 million raised in Series A funding from February 2022 to advance the development of new products utilizing their Sirona technology.

The company aims to expand its market presence beyond the UK, targeting additional European markets by 2023 as it progresses through clinical approvals. The funding will support clinical trials and commercialization efforts to enhance the scalability of its innovative health solutions.